Insulin is a peptide hormone of 51 amino acids, produced by the beta cells of the pancreatic islets of Langerhans. It is the single most important signal telling your body "fuel is available, store it." Insulin pulls glucose into cells, parks it as glycogen in liver and muscle, turns fatty acids into triglycerides in adipose, shuts down hepatic glucose output, and promotes protein synthesis. Every major metabolic disease of the modern era — type 1 diabetes, type 2 diabetes, metabolic syndrome, fatty liver — is a story about insulin not working properly.
At a glance
What it does
Insulin's core job is managing the shift between fed and fasting states. After a meal, rising glucose drives insulin release from beta cells. Insulin binds receptors on muscle, liver, and fat cells and orchestrates a coordinated anabolic response: glucose uptake and glycogen synthesis in muscle and liver, fatty acid synthesis and triglyceride storage in adipose, amino acid uptake and protein synthesis in muscle, and suppression of hepatic gluconeogenesis and lipolysis everywhere.
Between meals, insulin falls, and the counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone) take over. The liver starts releasing glucose, adipose releases fatty acids, and muscle spares glucose in favor of fatty acid oxidation. This coordinated back-and-forth is what keeps blood glucose stable across feeding and fasting, exercise and rest, sleep and waking.
Insulin is also not purely metabolic. It crosses into the brain via specialized transporters and modulates appetite, memory, and reward circuits. Brain insulin signaling is impaired in Alzheimer's disease — some researchers now call Alzheimer's "type 3 diabetes" as a compact way to describe that association.
How it works
Insulin synthesis starts as preproinsulin in beta cell ribosomes, gets processed to proinsulin in the endoplasmic reticulum, and finally cleaved into insulin and C-peptide in secretory granules. Insulin and C-peptide are released in a 1:1 ratio, which is why measuring C-peptide (with a longer half-life) is a standard way to assess endogenous insulin production — particularly useful in patients already on exogenous insulin.
Secretion is biphasic. When glucose rises, beta cells release a stored pool within minutes (first-phase), followed by a sustained second phase of newly synthesized insulin over 30-60 minutes. The first-phase release is blunted early in type 2 diabetes — long before fasting glucose drifts out of range. Loss of the first-phase response to an oral glucose tolerance test is one of the earliest detectable signs of beta cell dysfunction.
At target cells, insulin binds a tyrosine kinase receptor. Activation triggers IRS-1/IRS-2 phosphorylation, then splits into two main branches: the PI3K/Akt pathway drives glucose uptake, glycogen synthesis, and gene expression changes; the MAPK pathway drives growth and proliferation signals. Insulin resistance is primarily a defect in the PI3K/Akt branch while the MAPK branch keeps firing — which may explain why insulin resistance often coexists with growth and proliferative effects that drive atherosclerosis and some cancers.
Glucose uptake in muscle and fat happens via GLUT4 transporters normally sequestered inside the cell. Insulin causes GLUT4-containing vesicles to fuse with the plasma membrane, dramatically increasing glucose import. Exercise also triggers GLUT4 translocation through an insulin-independent pathway, which is why muscle activity lowers glucose even when insulin signaling is impaired.
Levels & ranges
Fasting insulin in healthy, metabolically intact adults typically runs 2-20 µIU/mL (sometimes expressed as 12-120 pmol/L). Values in the 5-10 µIU/mL range are considered more metabolically ideal than those in the 15-20 range, though individual lab reference ranges vary. A fasting glucose of 70-99 mg/dL is the normal range; 100-125 is pre-diabetes; 126 and above, confirmed on two occasions, is diabetes.
HbA1c reflects average glucose exposure over the previous three months by measuring glycated hemoglobin. Below 5.7% is normal; 5.7-6.4% is pre-diabetes; 6.5% and above is diabetes. HbA1c can be misleading in anemias and hemoglobinopathies — anything that shortens red cell lifespan underestimates HbA1c; anything that prolongs it overestimates.
HOMA-IR (fasting glucose in mg/dL × fasting insulin in µIU/mL / 405) is a simple insulin resistance estimate. Under 1 is excellent; 1-2 is reasonable; 2-3 is concerning; above 3 is frank resistance. HOMA-IR is not used much clinically because most physicians rely on A1c and fasting glucose alone, but it catches insulin resistance earlier.
Postprandial glucose (2 hours after a standardized meal) and the oral glucose tolerance test give a dynamic picture. In healthy subjects, 2-hour glucose stays below 140 mg/dL; 140-199 is impaired glucose tolerance; 200 and above meets diabetes criteria. A real mismatch between fasting labs and postprandial response is common — you can have normal fasting numbers while already showing substantial postmeal glucose excursions and compensatory hyperinsulinemia.
When it goes wrong
Type 1 diabetes is an autoimmune destruction of pancreatic beta cells. Most cases appear in childhood or adolescence but can present at any age. The result is absolute insulin deficiency — patients require lifelong exogenous insulin to survive. Without it, they go into diabetic ketoacidosis within days and die.
Type 2 diabetes is a different disease despite the shared name. It starts as insulin resistance — tissues become progressively less responsive to insulin, beta cells compensate by producing more, and for years or decades glucose looks normal while insulin is chronically elevated. Eventually beta cells decompensate, insulin production falls relative to demand, and glucose climbs out of range. The two core drivers are caloric excess and muscle disuse, layered on variable genetic susceptibility. Type 2 is broadly reversible with substantial weight loss (especially visceral fat) and muscle-building exercise, particularly if caught early before too much beta cell loss has accumulated.
Gestational diabetes appears during pregnancy as placental hormones induce insulin resistance; most cases resolve after delivery but signal elevated lifetime risk of type 2. MODY (maturity-onset diabetes of the young) is a family of rare monogenic diabetes forms that often get misdiagnosed as type 1 or type 2. Insulinomas — insulin-secreting tumors — cause recurrent hypoglycemia.
Metabolic syndrome is the constellation of central obesity, elevated triglycerides, low HDL, hypertension, and hyperglycemia that accompanies systemic insulin resistance. It dramatically raises cardiovascular risk even before frank diabetes appears. Nonalcoholic fatty liver disease (now called MASLD) is the hepatic expression of insulin resistance and has become the leading cause of chronic liver disease in developed countries.
Interactions
Body fat distribution matters more than total body fat. Visceral fat is metabolically active and drives insulin resistance through inflammatory cytokines and altered adipokines. A normal-BMI person with high visceral fat (sometimes called "TOFI" — thin outside, fat inside) can be more insulin resistant than a heavier subcutaneously-fat person.
Exercise is the most powerful modulator you can control without drugs. A single bout of resistance or endurance exercise improves insulin sensitivity for 24-48 hours. Regular training produces durable improvements through increased muscle mass (more storage capacity for glucose), improved mitochondrial function, and enhanced GLUT4 expression. Sleep deprivation impairs insulin sensitivity within days; chronic sleep restriction is quietly one of the most reliable ways to accelerate prediabetes.
Diet composition affects insulin response independent of calories. Refined carbohydrates and added sugars spike glucose and insulin much more than equivalent calories from fat or protein. Protein triggers modest insulin release independent of glucose. Fiber, fat, and protein all blunt the glycemic response to carbohydrates — meal composition, not just carb grams, is what matters.
Medications that improve insulin sensitivity include metformin, pioglitazone, GLP-1 agonists (see semaglutide), SGLT2 inhibitors, and bariatric surgery effects. Medications that worsen insulin sensitivity include corticosteroids (iatrogenic Cushing's in classic form), certain antipsychotics (olanzapine and clozapine especially), and high-dose thiazide diuretics. Cortisol itself is a major endogenous insulin antagonist — chronic stress contributes to metabolic dysfunction through this mechanism.
Honest take
The "carbs are evil" versus "calories are all that matter" debate has been running for two decades and both sides are oversimplifying. What actually holds up: muscle mass, visceral fat, and sleep are the three biggest levers. Dietary pattern matters, but the specific macronutrient ratio matters less than fiber intake, minimally processed whole food, and whether you can sustain the pattern. GLP-1 agonists have rewritten what is achievable for type 2 diabetes and obesity — they are not a cheat code, they are a genuine advance. On the flip side, continuous glucose monitors for non-diabetics can be useful for learning but also become an anxiety generator; most people would get more value from three months of strength training than from watching their glucose spike after a bagel.
Sources
- ADA Standards of Care in Diabetes (updated annually) — the reference document for diagnosis and management.
- DeFronzo, Diabetes (2009) — "From the Triumvirate to the Ominous Octet," the classic conceptual review of type 2 diabetes pathophysiology.
- Lean et al., DiRECT trial, The Lancet (2018) — demonstrated that substantial type 2 diabetes remission is achievable with sustained weight loss.
- Petersen & Shulman, Physiological Reviews — on the mechanisms of hepatic and muscle insulin resistance.